"Insights from Industry" is a dynamic series of interviews at the cutting edge of the life sciences industry.
Every interviewee is a leader in their particular field and is handpicked to give an informative and accessible
insight into their chosen field. These interviews are guaranteed to keep you in the know in a rapidly changing industry.
An interview with Charles Mazel, President of NIGHTSEA, conducted by Barbara Foster, The Microscopy & Imaging Place, Inc.
Dr. Thomas Mueller is the Director of Product Management in the AFM business unit of Bruker’s Nano Surfaces Division. Thomas has been with Bruker for 12 years having held positions in applications and product management, and is the author of over 50 publications, reviews, and application notes.
Mr. Mingjie Xie, MSc, MBA, is the co-founder and CEO of Rapid Novor Inc. He is a computer scientist by training andreceived his MSc degree from Western University in the field of bioinformatics. He received his MBA degree from Richard Ivey School of Business to pursue his interests in business. Prior to co-founding Rapid Novor Inc, Mingjie is the COO of a bioinformatics software company.
AFM is quite a versatile technique and we see a great potential of this technology for life science applications. It is still fairly new in Bio community, however very well accepted not only as imaging tools but as a versatile instrument for nanomechanical measurements.
Samuel Lesko has more than 20 years experiences in running AFM over variety of applications.
After obtaining a PhD at Burgundy university on colloidal force measurement in cement, he started his career at Veeco Instruments as French Applications Scientists before to continue on supporting Bio Applications AFM European wide. He is since 2007 Applications manager for Europe, Middle East and Africa. Recently, his position expanded to Latin America.
There's a continued drive towards making in vitro assays ever more translational towards in vivo models and ultimately the clinic. This ties in with the resurgence of phenotypic screening and is a response to the perceived poor translation of the traditional simple cell-based assays, often developed to study just single protein targets.
There are about 77,000 people known to have cystic fibrosis. That's from the various cystic fibrosis registries available globally. The World Health Organization suggests that this number may be low, because there's no reporting on cystic fibrosis from the developing world. The accepted number, at the moment, is about 80,000. That's the one that is used for most of the work that's being done on cystic fibrosis.
There are two problems that pathologists face today. The first is, that a pathologist’s diagnosis using tissue sections is becoming more complex. There are many more biomarkers, and clinicians now ask for a more precise diagnosis. Secondly, the number of pathologists worldwide is declining every day, as the profession is often overlooked in favor of other specializations.
There are two main things that we've worked on in the lab as regards to drug studies. One is identifying new combinations of drugs, and working on why a combination of drugs should work better than each alone.
Osmometry is a method to determine a sample´s osmolality. This is the total number of osmotically active particles solved in a solution. These particles influence the colligative properties of the solution, which include the boiling and freezing point but also the vapor pressure for instance.
My research uses budding yeast as a tool for synthetic biology, and also in chemical and functional genomic applications. We are interested in understanding molecular mechanisms and metabolic pathways of yeast for drug discovery.
Leveraging the mass production benefit that MultiBrain® technology brings to neurohistology, NSA can accelerate the R&D preclinical and safety assessment processes many fold and perform them less expensively. This results in faster times for a potential drug to move from R&D to clinical trials and sooner for use in people.
Jules Wyss is the head of the quality assurance laboratory at the largest brewery in Switzerland, the Feldschlösschen brewery in Rheinfelden. The master brewer and beverage technologist helped to set up the QA lab from 1991 onward.
The report set out the NHS’ intentions of routinizing whole genome sequencing. It is particularly focused towards rare diseases and cancers, although conditions such as obesity, bacterial and other infections are also included.
Every cell is a miniature factory taking in raw material (extracellular signals) and processing it to produce something (a biological response). But unlike a factory that can be easily tweaked to run at steady-state and look the same from day to day, cells are dynamic.
Species identification is important for ecological research and in particular to study the impact of natural hazards or environmental pollutants present, because it’s possible to determine the general health of the ecosystem through the diversity of life that are found in a given area.
The main challenges in optimizing beer shelf life is that most manufacturers can only perform accelerated shelf life testing on packaged beer. So, it's almost impossible to determine where in the process you've had a positive or a negative impact on the freshness of the beer.
There are two main challenges and both relate to manufacturing. The first one is to make sure you can manufacture therapies with reasonable costs and the second one is to make sure that you can balance the capacity you need with the demands.
This test, which we have branded SelectMDx for Prostate Cancer, came with the acquisition of a company in the Netherlands called NovioGendix. They developed a prototype assay, so they did most of the heavy lifting in terms of discovering the two specific biomarkers that are currently in the product. These biomarkers are tuned towards the detection of what I call clinically significant prostate cancer.
The first thing is, to always remember that we're dealing with a living drug, cells, which are very sensitive to environmental conditions, such as temperature and humidity etc. All of those things can impact on the viability of the drug and its effectiveness.